News | May 01, 2025
Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
ekincare has raised a total funding of $22M since 2015 till date
This approval authorizes the company to export Ibuprofen to the Chinese markets
The inspection concluded with 6 observations and none of them were related to Data Integrity
Investment demonstrates confidence in America’s commitment to science and innovation
Subscribe To Our Newsletter & Stay Updated
